Modern Myeloma Therapy + Sustained Minimal Residual Disease-Negative = (Functional) Cure!
作者信息
Landgren Ola, Kazandjian Dickran
机构信息
Myeloma Program, Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL.
出版信息
J Clin Oncol. 2022 Sep 1;40(25):2863-2866. doi: 10.1200/JCO.22.00622. Epub 2022 Jun 30.
Abstract
摘要
相似文献
1
Modern Myeloma Therapy + Sustained Minimal Residual Disease-Negative = (Functional) Cure!现代骨髓瘤疗法 + 持续微小残留病阴性 =（功能性）治愈！
J Clin Oncol. 2022 Sep 1;40(25):2863-2866. doi: 10.1200/JCO.22.00622. Epub 2022 Jun 30.
2
Longitudinal minimal residual disease assessment in multiple myeloma patients in complete remission - results from the NMSG flow-MRD substudy within the EMN02/HO95 MM trial.多发性骨髓瘤患者完全缓解后的纵向微小残留病灶评估——来自 EMN02/HO95 MM 试验中 NMSG 流式微小残留病灶子研究的结果。
BMC Cancer. 2022 Feb 5;22(1):147. doi: 10.1186/s12885-022-09184-1.
3
Assessment of response to therapy in multiple myeloma by multiparameter flow cytometry. Usefulness of an eight-color single tube with monoclonal antibodies in dried formulation.通过多参数流式细胞术评估多发性骨髓瘤的治疗反应。含单克隆抗体的八色单管干燥制剂的实用性。
Clin Ter. 2019 Sep-Oct;170(5):e352-e356. doi: 10.7417/CT.2019.2159.
4
Minimal Residual Disease in Multiple Myeloma: an Important Tool in Clinical Trials.多发性骨髓瘤中的微小残留病：临床试验中的重要工具。
Rev Recent Clin Trials. 2022;17(1):9-10. doi: 10.2174/1574887116666211123092915.
5
The prognostic value of multiparameter flow cytometry minimal residual disease assessment in relapsed multiple myeloma.多参数流式细胞术微小残留病评估在复发多发性骨髓瘤中的预后价值
Haematologica. 2015 Feb;100(2):e53-5. doi: 10.3324/haematol.2014.115162. Epub 2014 Nov 7.
6
Minimal residual disease in multiple myeloma: why, when, where.多发性骨髓瘤的微小残留病：为何、何时、何地。
Hematology Am Soc Hematol Educ Program. 2021 Dec 10;2021(1):37-45. doi: 10.1182/hematology.2021000230.
7
Controversies in the assessment of minimal residual disease in multiple myeloma: clinical significance of minimal residual disease negativity using highly sensitive techniques.多发性骨髓瘤微小残留病评估中的争议：使用高灵敏度技术检测微小残留病阴性的临床意义
Curr Hematol Malig Rep. 2014 Dec;9(4):368-78. doi: 10.1007/s11899-014-0237-y.
8
Prospective trial of minimal residual disease assessment by multiparametric flow cytometry for multiple myeloma in the era of bortezomib-based chemotherapy.硼替佐米为主的化疗时代，多参数流式细胞术评估多发性骨髓瘤微小残留病的前瞻性试验
Bone Marrow Transplant. 2018 Dec;53(12):1589-1592. doi: 10.1038/s41409-018-0241-2. Epub 2018 Jun 18.
9
Latest treatment strategies aiming for a cure in transplant-eligible multiple myeloma patients: how I cure younger MM patients with lower cost.适合移植的多发性骨髓瘤患者的最新治疗策略：我如何用更低的成本治愈年轻的多发性骨髓瘤患者。
Int J Hematol. 2020 Apr;111(4):512-518. doi: 10.1007/s12185-020-02841-w. Epub 2020 Mar 3.
10
Flow Cytometry-Based Photodynamic Diagnosis with 5-Aminolevulinic Acid for the Detection of Minimal Residual Disease in Multiple Myeloma.基于流式细胞术的 5-氨基酮戊酸光动力诊断在多发性骨髓瘤微小残留病检测中的应用。
Tohoku J Exp Med. 2019 Sep;249(1):19-28. doi: 10.1620/tjem.249.19.
引用本文的文献
1
Targeting high-risk multiple myeloma genotypes with optimized anti-CD70 CAR-T cells.使用优化的抗CD70嵌合抗原受体T细胞靶向高危多发性骨髓瘤基因型。
bioRxiv. 2024 Feb 28:2024.02.24.581875. doi: 10.1101/2024.02.24.581875.
2
Clinical Benefit of Autologous Stem Cell Transplantation for Patients with Multiple Myeloma Achieving Undetectable Minimal Residual Disease after Induction Treatment.诱导治疗后达到微小残留病灶不可检测的多发性骨髓瘤患者自体干细胞移植的临床获益。
Cancer Res Commun. 2023 Sep 6;3(9):1770-1780. doi: 10.1158/2767-9764.CRC-23-0185. eCollection 2023 Sep.
3
Selinexor: Targeting a novel pathway in multiple myeloma.塞利尼索：靶向多发性骨髓瘤的一条新途径。
EJHaem. 2023 May 15;4(3):792-810. doi: 10.1002/jha2.709. eCollection 2023 Aug.
本文引用的文献
1
Minimal Residual Disease After Autologous Stem-Cell Transplant for Patients With Myeloma: Prognostic Significance and the Impact of Lenalidomide Maintenance and Molecular Risk.自体干细胞移植后多发性骨髓瘤患者的微小残留病：预后意义和来那度胺维持治疗及分子风险的影响。
J Clin Oncol. 2022 Sep 1;40(25):2889-2900. doi: 10.1200/JCO.21.02228. Epub 2022 Apr 4.
2
Early versus late response to daratumumab-based triplet therapies in patients with multiple myeloma: a pooled analysis of trials POLLUX, CASTOR and MAIA.基于达雷妥尤单抗的三联疗法治疗多发性骨髓瘤患者的早期与晚期应答：POLLUX、CASTOR 和 MAIA 试验的汇总分析。
Leuk Lymphoma. 2022 Jul;63(7):1669-1677. doi: 10.1080/10428194.2022.2038376. Epub 2022 Feb 10.
3
NCCN Guidelines® Insights: Multiple Myeloma, Version 3.2022.美国国立综合癌症网络（NCCN）指南见解：多发性骨髓瘤，2022年第3版
J Natl Compr Canc Netw. 2022 Jan;20(1):8-19. doi: 10.6004/jnccn.2022.0002.
4
Prognostic value of minimal residual disease negativity in myeloma: combined analysis of POLLUX, CASTOR, ALCYONE, and MAIA.骨髓瘤中微小残留病阴性的预后价值：POLLUX、CASTOR、ALCYONE和MAIA的联合分析
Blood. 2022 Feb 10;139(6):835-844. doi: 10.1182/blood.2021011101.
5
Dynamics of minimal residual disease in patients with multiple myeloma on continuous lenalidomide maintenance: a single-arm, single-centre, phase 2 trial.来那度胺持续维持治疗的多发性骨髓瘤患者微小残留病动态变化：一项单臂、单中心2期试验
Lancet Haematol. 2021 Jun;8(6):e422-e432. doi: 10.1016/S2352-3026(21)00130-7.
6
Safety and Effectiveness of Weekly Carfilzomib, Lenalidomide, Dexamethasone, and Daratumumab Combination Therapy for Patients With Newly Diagnosed Multiple Myeloma: The MANHATTAN Nonrandomized Clinical Trial.每周卡非佐米、来那度胺、地塞米松和达雷妥尤单抗联合治疗新诊断多发性骨髓瘤患者的安全性和有效性：MANHATTAN 非随机临床试验。
JAMA Oncol. 2021 Jun 1;7(6):862-868. doi: 10.1001/jamaoncol.2021.0611.
7
Revealing the impact of structural variants in multiple myeloma.揭示多发性骨髓瘤中结构变异的影响。
Blood Cancer Discov. 2020 Nov;1(3):258-273. doi: 10.1158/2643-3230.BCD-20-0132. Epub 2020 Sep 15.
8
A large meta-analysis establishes the role of MRD negativity in long-term survival outcomes in patients with multiple myeloma.一项大型荟萃分析确立了 MRD 阴性在多发性骨髓瘤患者长期生存结局中的作用。
Blood Adv. 2020 Dec 8;4(23):5988-5999. doi: 10.1182/bloodadvances.2020002827.
9
Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial.达雷妥尤单抗、来那度胺、硼替佐米和地塞米松用于适合移植的新诊断多发性骨髓瘤：GRIFFIN 试验。
Blood. 2020 Aug 20;136(8):936-945. doi: 10.1182/blood.2020005288.
10
Timing the initiation of multiple myeloma.多发性骨髓瘤的起始时机。
Nat Commun. 2020 Apr 21;11(1):1917. doi: 10.1038/s41467-020-15740-9.
Zotero 插件